Compugen Ltd (CGEN)

$0.6643

Market is closed - opens 8 PM, 01 Dec 2023

Insights on Compugen Ltd

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 75.9% return, outperforming this stock by 120.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 25.4% return, outperforming this stock by 120.2%

Performance

  • $0.65
    $0.67
    $0.66
    downward going graph

    1.08%

    Downside

    Day's Volatility :2.55%

    Upside

    1.49%

    downward going graph
  • $0.53
    $1.49
    $0.66
    downward going graph

    19.7%

    Downside

    52 Weeks Volatility :64.43%

    Upside

    55.7%

    downward going graph

Returns

PeriodCompugen LtdSector (Health Care)Index (Russel 2000)
3 Months
-41.32%
-3.8%
0.0%
6 Months
-36.89%
2.3%
0.0%
1 Year
-44.25%
-6.7%
-6.2%
3 Years
-94.79%
18.2%
-2.8%

Highlights

Market Capitalization
56.7M
Book Value
$0.6
Dividend Share
0.0
Dividend Yield
3.38%
Earnings Per Share (EPS)
-0.37
PEG Ratio
0.0
Wall Street Target Price
4.67
Profit Margin
0.0%
Operating Margin TTM
-460.07%
Return On Assets TTM
-25.83%
Return On Equity TTM
-47.44%
Revenue TTM
7.5M
Revenue Per Share TTM
0.09
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
6.5M
EBITDA
-34.0M
Diluted Eps TTM
-0.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.26
EPS Estimate Next Year
-0.52
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Compugen Ltd(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 603.0%

Current $0.66
Target $4.67

Technicals Summary

Sell

Neutral

Buy

Compugen Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Compugen Ltd
Compugen Ltd
-2.34%
-36.89%
-44.25%
-94.79%
-80.66%
Moderna, Inc.
Moderna, Inc.
6.67%
-37.2%
-55.08%
-48.27%
324.78%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.98%
10.98%
7.57%
56.69%
121.14%
Novo Nordisk A/s
Novo Nordisk A/s
5.81%
27.65%
63.72%
203.89%
337.58%
Seagen, Inc.
Seagen, Inc.
-0.29%
10.06%
75.9%
25.37%
241.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.8%
7.9%
10.94%
54.12%
94.15%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Compugen Ltd
Compugen Ltd
NA
NA
0.0
-0.26
-0.47
-0.26
0.03
0.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Compugen Ltd
Compugen Ltd
Buy
$56.7M
-80.66%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
324.78%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
121.14%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
337.58%
43.04
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
241.2%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
94.15%
26.52
35.94%

Corporate Announcements

  • Compugen Ltd Earnings

    Compugen Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen’s wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib

Organization
Compugen Ltd
Employees
69
CEO
Dr. Anat Cohen-Dayag Ph.D.
Industry
Health Technology

Discover More

FAQs